China Resources Shuanghe: Holding subsidiary Sodium Valproate API obtained CEP Certificate.

China Resources Shuanghe announced that its subsidiary Shuanghe Xiangzhong recently received a Certificate of Suitability for Sodium Valproate Active Substance (CEP) issued by the European Medicines Agency. Shuanghe Xiangzhong started the registration work in June 2024 and obtained the certificate on June 26, 2026. As of the announcement date, the company has invested 41,500 RMB in the registration and development of this active substance. There are a total of 14 companies in mainland China that have been approved for the production of Sodium Valproate Active Substance, and there are 8 global holders of Sodium Valproate CEP certificates. This matter has no major impact on current performance, and there is uncertainty in international business.